Corneal Collagen Crosslinking and Intacs for Keratoconus and Ectasia (CXL)

Study Description

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Brief Summary:

This study will determine the efficacy of corneal collagen crosslinking (CXL) combined with Intacs for the treatment of keratoconus and corneal ectasia. The goal of CXL is to decrease the progression of keratoconus, while Intacs has been shown to decrease corneal steepness in keratoconus. This study will attempt to determine the relative efficacy of the two procedures either performed at the same session versus CXL performed 3 months after Intacs.

Condition or disease	Intervention/treatment	Phase
Keratoconus; Corneal Ectasia	Drug: Riboflavin	Phase 3

Detailed Description:

The purpose of this is to ascertain the possible additive effect of the two treatments to both improve the quality of the corneal optics (i.e. improve corneal topography regularity) and to stabilize the cornea. Previous investigations have shown that Intacs surgery, indeed, does improve corneal topography and improve contact lens tolerance and spectacle corrected visual acuity, as well as uncorrected visual acuity in some patients. Investigations of CXL have shown the procedure not only to decrease keratoconus progression, but also to decrease the steepness of the cone and improve uncorrected and best corrected visual acuity in some cases. Since the mechanism of improvement differs between the procedures, this suggests a potential additive effect of the two on the patient's ultimate visual outcome. Thus, the patient would be afforded two potential benefits: (1) the potential of a more robust visual outcome and (2) stabilization of the keratoconic cornea on the longer term.

Study Design

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Study Type :	Interventional (Clinical Trial)
Estimated Enrollment :	160 participants
Allocation:	Randomized
Intervention Model:	Parallel Assignment
Masking:	None (Open Label)
Primary Purpose:	Treatment
Official Title:	Randomized Study of Safety and Effectiveness of Corneal Collagen Crosslinking and Intacs for Treatment of Keratoconus and Corneal Ectasia
Study Start Date :	April 2010
Estimated Primary Completion Date :	December 2018
Estimated Study Completion Date :	December 2018

Arms and Interventions

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm	Intervention/treatment
Active Comparator: Intacs combined with CXL; Intacs placement followed by collagen crosslinking with UV light and riboflavin	Drug: Riboflavin; Corneal epithelium removed followed by riboflavin drop administration every 2 minutes for 30 minutes followed by UV light exposure with additional riboflavin administration every 2 minutes for 30 minutes. Subjects will be randomized to receive Intacs placement either immediately before CXL or 3 months before CXL.; Other Names: Intracorneal Ring Segments; Cornea Collagen Crosslinking
Active Comparator: Intacs followed by CXL; Intacs placement, to be followed by corneal collagen crosslinking with UV light and riboflavin 3 months later	Drug: Riboflavin; Corneal epithelium removed followed by riboflavin drop administration every 2 minutes for 30 minutes followed by UV light exposure with additional riboflavin administration every 2 minutes for 30 minutes. Subjects will be randomized to receive Intacs placement either immediately before CXL or 3 months before CXL.; Other Names: Intracorneal Ring Segments; Cornea Collagen Crosslinking

Outcome Measures

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :

1. Maximum keratometry [ Time Frame: 1 year ]

Secondary Outcome Measures :

1. Best Corrected Visual Acuity [ Time Frame: 1 year ]

Eligibility Criteria

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Ages Eligible for Study:	21 Years and older (Adult, Senior)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

• 21 years of age or older
• Having a diagnosis of keratoconus or corneal ectasia after corneal refractive surgery (e.g., LASIK, photorefractive keratectomy [PRK], or epi-LASIK)
• Subjects who meet the manufacturer's nomogram recommendations for Intacs segments
• Topography consistent with keratoconus or post-surgical corneal ectasia.
• BSCVA worse than 20/20 (<55 letters on ETDRS chart)

Exclusion Criteria:

• Eyes classified as either normal, atypical normal, or keratoconus suspect on the severity grading scheme.
• Corneal pachymetry ≤ 400 microns at the thinnest point measured by Pentacam in the eye(s) to be treated when the isotonic riboflavin solution is used or ≤ 300 microns when the hypotonic riboflavin us used, provided that the corneal thickness after treatment with the hypotonic riboflavin solution is > 400 microns. Corneal pachymetry ≤ 450 microns at the proposed insertion site for the Intacs
• Previous ocular condition (other than refractive error) in the eye(s) to be treated that may predispose the eye for future complications
• History of corneal disease
• History of chemical injury or delayed epithelial healing in the eye(s) to be treated.
• Pregnancy (including plan to become pregnant) or lactation during the course of the study
• A known sensitivity to study medications
• Subjects with nystagmus or any other condition that would prevent a steady gaze during the CXL and Intacs treatment or other diagnostic tests.
• Subjects with a current condition that, in the investigator's opinion, would interfere with or prolong epithelial healing.

Contacts and Locations

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Locations

United States, New Jersey
Cornea and Laser Eye Institute
Teaneck, New Jersey, United States, 07666

Sponsors and Collaborators

Cornea and Laser Eye Institute

Investigators

Principal Investigator:	Peter Hersh, M.D.	Cornea and Laser Eye Institute

More Information

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Responsible Party:	Cornea and Laser Eye Institute
ClinicalTrials.gov Identifier:	NCT01112072 History of Changes
Other Study ID Numbers:	CLEI-Intacs-CXL
First Posted:	April 28, 2010
Last Update Posted:	January 25, 2018
Last Verified:	January 2018

Keywords provided by Cornea and Laser Eye Institute:

keratoconus; corneal ectasia; collagen crosslinking	riboflavin; cornea; ultraviolet

Additional relevant MeSH terms:

Keratoconus; Dilatation, Pathologic; Corneal Diseases; Eye Diseases; Pathological Conditions, Anatomical; Riboflavin; Vitamin B Complex	Vitamins; Micronutrients; Growth Substances; Physiological Effects of Drugs; Photosensitizing Agents; Dermatologic Agents